【摘要】 目的　研究肿瘤组织中纤溶成份的表达与肿瘤进展和术后生存时间的关系。方法　用Northern印迹和免疫组化法研究 10例正常食管和 4 1例食管癌标本中的尿激酶型纤溶酶原激活物(uPA)、尿激酶型纤溶酶原激活物受体 (uPAR)和纤溶酶激活抑制物 1(PAI 1)。结果　食管癌标本中uPA、uPAR和PAI 1mRNA表达比正常食管分别升高 5 .1,3 .7和 12倍 (P <0 .0 1)。在不同的肿瘤分化程度、不同的TNM分期、不同的组织学类型之间uPA、uPAR和PAI 1的表达差异不显著。肿瘤中uPA和uPAR同步升高的患者与其他患者相比 ,其术后生存时间差异无显著性。结论　本研究表明 ,uPA、uPAR和PAI 1在食管癌组织中均明显升高 ,但这种升高与肿瘤进展和术后生存时间无关。更多还原

【Abstract】 Objective Expression of uPA (urokinase type plasminogen activator), uPAR(urokinase type plasminogen activator receptor) and PAI 1 (plasminogen activator inhibitor 1) in esophageal cancerous tissues, and its correlation with postoperative survival were investigated. Methods Esophageal cancerous tissues specimens were obtained from 41 patients underwent esophageal resection. 10 normal esophageal tissue samples were obtained from healthy individials during multiorgan donation for transplantation. The mRNA expressions of uPA, uPAR and PAI 1 were analyzed by Northern blot analysis. In addition, immunohistochemical analysis of uPA, uPAR and PAI 1 were compared with histopathological and clinical data. Results Northern blot analysis revealed a 5.1 fold, 3.7 fold and 12.0 fold increase in uPA, uPAR, and PAI 1 mRNA levels in esophageal cancer, respectively, compared with normal controls ( P <0.01). Semiquantitative immunohistochemical analysis of uPA, uPAR and PAI 1 revealed increased immunostaining in 41.5%, 41.5% and 48.8% of the cancer samples. Statistical analysis revealed no differences in uPA, uPAR and PAI 1 immunoreactivity between well , moderately and poorly differentiated tumors. Furthermore, survival analysis showed no difference in patients whose tumors exhibited positive uPA and uPAR immunostaining (median 11 months) versus those with negative uPA and uPAR immunostaining (median 11 months). Conclusion Our data reveal that concomitant overexpression of uPA, uPAR and PAI 1 are often present in human esophageal carcinomas. However, upregulation of these factors are not correlated with tumor differentiation or survival. These findings indicate that uPA, uPAR, and PAI 1 are not prognostic markers in esophageal carcinoma.更多还原